Emyria Launches Global Platform to Support Drug Developers.
Emyria Limited (ASX: EMD) has unveiled a new global services platform designed to assist international drug developers, signalling a key evolution in its growth strategy. The initiative introduces a dual-income model by adding sponsor-funded services to its existing treatment operations. By utilising its established clinical network, skilled workforce, and specialised facilities, the company aims to support the delivery of complex mental health therapies, including emerging psychedelic-based treatments.
With a growing number of such therapies under development worldwide, the need for reliable clinical delivery infrastructure has become increasingly important. Emyria’s platform addresses this gap by enabling efficient execution of clinical programs and facilitating expansion into commercial treatment phases. Early traction is demonstrated through its work with Psyence Group, while increasing engagement from global partners highlights strong demand and positions Emyria for further growth in this evolving sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Emyria Launches Global Platform to Support Drug Developers.
Emyria Limited (ASX: EMD) has unveiled a new global services platform designed to assist international drug developers, signalling a key evolution in its growth strategy. The initiative introduces a dual-income model by adding sponsor-funded services to its existing treatment operations. By utilising its established clinical network, skilled workforce, and specialised facilities, the company aims to support the delivery of complex mental health therapies, including emerging psychedelic-based treatments.
With a growing number of such therapies under development worldwide, the need for reliable clinical delivery infrastructure has become increasingly important. Emyria’s platform addresses this gap by enabling efficient execution of clinical programs and facilitating expansion into commercial treatment phases. Early traction is demonstrated through its work with Psyence Group, while increasing engagement from global partners highlights strong demand and positions Emyria for further growth in this evolving sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au